<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554434</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-99</org_study_id>
    <nct_id>NCT03554434</nct_id>
  </id_info>
  <brief_title>An Expanded Access Program for AM0010 (Pegilodecakin)</brief_title>
  <official_title>An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <brief_summary>
    <textblock>
      This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who
      have failed or progressed on standard of care systemic therapy and do not qualify for ongoing
      clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Melanoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Solid Tumors</condition>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>AM0010</description>
    <other_name>LY3500518</other_name>
    <other_name>Pegilodecakin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Patient is NOT eligible for other AM0010 clinical trials currently open in the region

          -  Patient is in urgent need of therapy who fail to meet eligibility criteria for other
             clinical trials related to AM0010 (PEG-IL-10) can be considered for enrollment into
             this Expanded Access Program.

          -  Patient has advanced cancer in indications where preliminary anti-tumor efficacy of
             AM0010 has been demonstrated or where AM0010 mediated immune activation is likely to
             benefit the patient.

          -  Patient has failed or progressed on standard of care (SOC) systemic therapy

          -  Patient is refusing SOC therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Contact Lilly at 1-800-LillyRx (1-800-545-5979)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 31, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

